Core Points - MapLight Therapeutics, Inc. has priced its initial public offering (IPO) at $17.00 per share for 14,750,000 shares, with an additional option for underwriters to purchase 2,212,500 shares [1][2] - The total expected gross proceeds from the IPO and a concurrent private placement are approximately $258.9 million, excluding underwriters' options and expenses [2] - The shares are set to begin trading on the Nasdaq Global Market under the symbol "MPLT" on October 27, 2025, with the offering expected to close on October 28, 2025 [3] Company Overview - MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on central nervous system disorders, founded by leaders in psychiatry and neuroscience [7] - The company's lead product candidate, ML-007C-MA, is currently in Phase 2 clinical trials for treating schizophrenia and Alzheimer's disease psychosis [7]
MapLight Therapeutics Announces Pricing of Initial Public Offering